November 8, 2021
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
October 18, 2021
Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion
September 13, 2021
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
September 3, 2021
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association
August 18, 2021
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association
August 12, 2021
Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer
July 6, 2021
Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
June 29, 2021
Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder
April 15, 2021
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
April 12, 2021
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
February 12, 2021
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
February 11, 2021
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board